1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Hold On TG’s Program Stems From Existing – Not New – Concerns

‘Sub-par’ Disclosure Draws Analyst Finger Wagging

 
• By Alaric DeArment

TG expects overall survival hazard ratios to move closer to those of existing CLL drugs. Some analysts called a drop in the company’s shares overblown.

Digital illustration of Cancer cell in colour background
TG disclosed a partial clinical hold on its program to develop Ukoniq/ublituximab in NHL and CLL • Source: Shutterstock

The partial clinical hold on TG Therapeutics, Inc.’s program for PI3K-delta inhibitor Ukoniq (umbralisib) combined with CD20-directed ublituximab – together nicknamed U2 – does not appear to be about any new concerns about Ukoniq. However, it does highlight concerns about the PI3K class overall and the method by which the company disclosed the hold drew criticism.

TG’s CEO Michael Weiss revealed in a fireside chat at B. Riley Securities’ 2022 Virtual Oncology Investor Conference on 27...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.